Carlsmed, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $392.6M
- Price
- $14.38
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.78%
- Volume
- 52.1K
About
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
Quick stats
Shares outstanding27.3M
Computed float9.7M
Float / shares35.4%
Key info
SectorHealthcare
IndustryMedical - Healthcare Information Services
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001794546
Websitehttps://www.carlsmed.com
AI Summary
AI-generated1/23
minorneutralexecutive change
Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Carlsmed granted inducement equity awards to newly hired CFO Richard Heppenstall on September 28, 2026: stock options for 180,137 shares plus 89,286 RSUs.
On October 1, 2026, the company granted new Chief Product and AI Officer Anthony Jarc options for 132,464 shares plus 63,735 RSUs, both outside the equity plan under Nasdaq Listing Rule 5635(c)(4).
The grants vest over four years (options) and three years (RSUs) and signal a build-out of the executive team, but imply modest incremental dilution for shareholders.
Red flags
- equity grants made outside the shareholder-approved equity incentive plan (inducement grants)